@Ah_Meng:ChatGPT AI Today I am trying something new. I have not used this Post function before in 🐯 app, so testing for the first time. Riding on @LMSunshine  post on the pick-and-shovel plays amidst the recent AI craze, I want to talk about a totally different topic. It is not about companies selection or stocks but purely AI chat! How much do you trust AI? ChatGPT AI launch and the subsequent funding round has created a lot of buzz in the AI space. The craze has generated a lot of hot air... Companies that have been working quietly in the space and those using AI for years suddenly grown in prominence... Out of nothing of their own designs! So how good and accurate is really ChatGPT AI to generate this craze? I understand in fact it

@Mexicools:$SINO-OCEAN GP(03377)$   Consensus EPS estimates increase by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2022 has improved. ◈2022 revenue forecast increased from CN¥57.7b to CN¥59.2b. ◈EPS estimate increased from CN¥0.205 to CN¥0.258 per share. ◈Net income forecast to grow 361% next year vs 15% growth forecast for Real Estate industry in Hong Kong. ◈Consensus price target broadly unchanged at HK$1.56. ◈Share price rose 3.7% to HK$1.13 over the past week.

@Jasmine1205:$BioNTech SE(BNTX)$  bearish Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022.